抗帕金森病药物的治疗评价与新药研究进展  

Therapeutic Evaluation of Anti-Parkinson's Disease Drugs and Research and Development of New Drugs

作　　者：徐雅楠 赵志刚[1] XU Yanan;ZHAO Zhigang(Department of Pharmacy,Beijing Tiantan Hospital,Capital Medical University,Beijing 100070,China)

机构地区：[1]首都医科大学附属北京天坛医院药学部,北京100070

出　　处：《医药导报》2023年第8期1178-1186,共9页Herald of Medicine

基　　金：北京市医院管理局临床医学发展专项扬帆计划项目(ZYLX201827)。

摘　　要：帕金森病(PD)是一种神经退行性疾病,无法治愈,甚至没有很好的方法阻止疾病进展。PD的治疗药物种类有限,均为对症治疗,药物靶点主要局限于中枢多巴胺能系统(如多巴胺前体药物、多巴胺受体激动剂、多巴胺代谢酶抑制剂等),治疗的同时可能会带来副作用或并发症。由于PD患者人群庞大,许多制药企业及科研人员投入大量精力研发PD新药,取得了一定成果。为充分了解PD的治疗现状和未来,了解PD新药的发展方向,该文就各类PD治疗药物的作用特点、疗效、安全性做一总结,并对进入临床试验的PD新药进行综述。As a neurodegenerative disease,Parkinson's disease(PD)is hard to be cured.There are even no good methods to prevent its progression.Therapeutic durgs for PD are limited and only used for symptomatic control.Dopaminergic system is the major target for anti-PD drugs(such as dopamine precursor drug levodopa,dopamine receptor agonists,and dopamine metabolizing enzyme inhibitors),but side effects or complications may accompany the treatment.Due to the large population of PD patients,many pharmaceutical companies and researchers have invested a lot of efforts in developing new drugs for PD in order to develop more therapeutic and effective drugs,and certain results have been achieved.In order to help related professionals fully understand the current status and future of PD treatment and the development direction of anti-PD new drugs,this paper summarizes the characteristics,efficacy and safety of various PD therapeutic drugs,and reviews new anti-PD drugs in clinical trials in recent years.

关 键 词：帕金森病 药物治疗 药物评价 

分 类 号：R971.5[医药卫生—药品] R742.5[医药卫生—药学]